User login
Key clinical point: Both recurrence-free survival and overall survival were higher in cirrhotic HCC patients without macrovascular invasion who had tumors of 5 cm or less compared to those with larger tumors.
Major finding: The rates of 5-year recurrence-free survival and overall survival were higher in patients with tumors of 5 cm or less compared to those with tumors greater than 5 cm (38.3% vs 25.1% and 61.5% vs 59.9%, respectively).
Study details: The data come from a retrospective study of 813 cirrhotic adults with solitary HCC without macrovascular invasion who underwent curative hepatectomy between 2001 and 2014. Tumor size was categorized as 5 cm or less (464 patients) or greater than 5 cm (349 patients).
Disclosures: The study was supported by the Natural Science Foundation of Hubei Province of China and the National Science and Technology Major Project of China. The researchers had no financial conflicts to disclose.
Source: Liang B-Y et al. Sci Rep. 2021 Aug 11. doi: 10.1038/s41598-021-95835-5.
Key clinical point: Both recurrence-free survival and overall survival were higher in cirrhotic HCC patients without macrovascular invasion who had tumors of 5 cm or less compared to those with larger tumors.
Major finding: The rates of 5-year recurrence-free survival and overall survival were higher in patients with tumors of 5 cm or less compared to those with tumors greater than 5 cm (38.3% vs 25.1% and 61.5% vs 59.9%, respectively).
Study details: The data come from a retrospective study of 813 cirrhotic adults with solitary HCC without macrovascular invasion who underwent curative hepatectomy between 2001 and 2014. Tumor size was categorized as 5 cm or less (464 patients) or greater than 5 cm (349 patients).
Disclosures: The study was supported by the Natural Science Foundation of Hubei Province of China and the National Science and Technology Major Project of China. The researchers had no financial conflicts to disclose.
Source: Liang B-Y et al. Sci Rep. 2021 Aug 11. doi: 10.1038/s41598-021-95835-5.
Key clinical point: Both recurrence-free survival and overall survival were higher in cirrhotic HCC patients without macrovascular invasion who had tumors of 5 cm or less compared to those with larger tumors.
Major finding: The rates of 5-year recurrence-free survival and overall survival were higher in patients with tumors of 5 cm or less compared to those with tumors greater than 5 cm (38.3% vs 25.1% and 61.5% vs 59.9%, respectively).
Study details: The data come from a retrospective study of 813 cirrhotic adults with solitary HCC without macrovascular invasion who underwent curative hepatectomy between 2001 and 2014. Tumor size was categorized as 5 cm or less (464 patients) or greater than 5 cm (349 patients).
Disclosures: The study was supported by the Natural Science Foundation of Hubei Province of China and the National Science and Technology Major Project of China. The researchers had no financial conflicts to disclose.
Source: Liang B-Y et al. Sci Rep. 2021 Aug 11. doi: 10.1038/s41598-021-95835-5.